and correlates of testing and (2) trends in testing, including before and after the 2007 USPSTF and 2008 AAP cholesterol statements.
Methods | We performed a repeated cross-sectional analysis of cholesterol testing among patients aged 2 to 21 years seen by pediatric, internal medicine, or general or family medicine clinicians from 1995 through 2010 at health maintenance visits. The NAMCS generates nationally representative estimates via a multistage probability sample design using 112 geographic sampling units, clinicians within these units, and patient visits. Patient visits are assigned a weight equal to the inverse probability of that sampled visit. Data 6 include patient demographics, type of visit (health maintenance, acute problem), physician specialty, practice setting, diagnoses, and medications (Table) . Height and weight were recorded from 2005 through 2010 and were missing approximately 18% of the time. To ensure complete data on race, we used the NAMCS imputed race variable for 36% of the visits.
Using logistic regression models within a time series analysis, we examined trends in cholesterol testing before and after 2007-2008, the years the USPSTF and AAP released their statements. We modeled the trend in testing rate by including year (1995-2010, skipping 2007 and 2008) as a continuous variable, with 2 levels for 2009-2010. Using the model output, we compared (1) the trend in testing rates through 2009-2010 if the statements had no effect and (2) the actual testing rates. We also ran logistic regression models to examine associations of patient, clinician, and geographic characteristics with cholesterol testing, amalgamated across years. We used SAS version 9.3 (SAS Institute Inc). The Harvard Pilgrim Health Care institutional review board deemed this analysis exempt from review.
Results | During the 16-year period, clinicians ordered cholesterol testing at 3.4% (95% CI, 3.1%-3.8%) of 10 159 health maintenance visits. Testing rates increased only slightly from 2.5% (95% CI, 0.4%-4.7%) in 1995 to 3.2% (95% CI, 2.0%-4.5%) in 2010 (P = .03 for unadjusted trend). 
COMMENT & RESPONSE

Drugs for the Treatment of Obesity
To the Editor The review 1 by Dr Yanovski and Dr Yanovski on the treatment of obesity focused on drugs currently approved by the US Food and Drug Administration for longterm treatment, which includes orlistat, phenterminetopiramate, and lorcaserin. The discussion of the mechanisms of action of the latter 2 drugs was limited to their appetitesuppressive effects. However, these medications also have major psychotropic properties. Phentermine is structurally and functionally similar to dexamphetamine, with similar clinical effects on mood and motivation. 2 Topiramate can lead to mood changes, including improvement or worsening of depression. 3 Lorcaserin reduces impulsive responses. 4 The psychotropic effects of these medications on mood, motivation, and impulse control are related to dosage and are of great relevance to the success of the lifestyle interventions that are combined with medication for achieving long-term weight control. The review reported that these important psychotropic properties tend to be overlooked.
Future research should consider all the clinical effects of these drugs, with the aim of titrating the dose to maximize their therapeutic potential. This includes optimizing the psychotropic effects that could assist with establishing the lifestyle changes that are integral to the success of the long-term treatment of obesity.
Alison Poulton, MA, MBBChir, MD Ralph Nanan, DrMedHabil
In Reply We agree with Drs Poulton and Nanan that the psychotropic actions of weight-loss medications are potentially of great importance, particularly given that most obesity medications approved or in development affect neurotransmitters that may have an effect on mood, cognition, or behavior. Some of these effects, such as negative mood or irritability, may be problematic, whereas others may potentially enhance ability to adhere to diet and exercise recommendations.
Assessment of all risks and benefits should be part of the considerations for clinicians selecting obesity medications for their patients. Space considerations limited discussion of many adverse consequences of medications in the text but they were included in the online Supplement. Additional studies are required to elucidate how psychotropic effects, such as reduction in impulsivity, may help to determine response to specific obesity medications.
